Comparative Pharmacology
Head-to-head clinical analysis: BUTAZOLIDIN versus PEDIATRIC ADVIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTAZOLIDIN versus PEDIATRIC ADVIL.
BUTAZOLIDIN vs PEDIATRIC ADVIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis. Also has uricosuric effect at higher doses.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
Butazolidin (phenylbutazone) is typically administered orally at 100-200 mg 3 times daily with meals, not to exceed 600 mg/day. Initial loading dose of 400 mg may be given on day 1, followed by 300-400 mg/day in divided doses. Duration should be limited to 7-10 days.
Ibuprofen 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
None Documented
None Documented
Terminal half-life: 50-100 hours (prolonged in elderly or hepatic/renal impairment; accumulation risk evident within 5-7 days).
Terminal elimination half-life is approximately 2-4 hours in children. Clinical context: rapid clearance; requires frequent dosing every 6-8 hours for sustained antipyretic/analgesic effect.
Primarily renal: ~60% as unchanged drug and glucuronide conjugates; biliary/fecal: ~40% (enterohepatic circulation).
Renal excretion of conjugated metabolites (glucuronides and sulfates) accounts for >90% of an administered dose, with <1% excreted unchanged. Biliary/fecal elimination is minimal (<5%).
Category C
Category C
NSAID
NSAID